abstract |
The amorphous nelfinavir mesylate solid dosage unit form of the invention comprises amorphous nelfinavir mesylate and a pharmaceutically acceptable, water-soluble, nonionic block copolymer of ethylene oxide and propylene oxide having a melting point of at least 40 ° C. The invention further relates to a wet melt granulation process for the preparation of the above dosage form. SHE |